Reporter Zhao Chenxi from our newspaper recently learned from the National Medical Security Administration that after the expiry of the national organization’s centralized procurement agreement for coronary stents, the selection results were produced in Changzhou, Jiangsu Province. A total of 14 products from 10 companies were eligible for the selection. The rate reached 91%, and the average price of the selected stent was about 770 yuan. It is expected that patients will use the selected products purchased continuously in January 2023.
The relevant person in charge of the National Medical Insurance Bureau said that since the national organization’s centralized procurement of coronary stents was implemented in January 2021, the overall operation has been stable.
This continuation procurement is the first time to explore the unified implementation of continuation work nationwide. A total of 3,696 medical institutions participated in the declaration, and the purchase volume was about 1.78 million. Compared with the previous round of centralized procurement, the number of medical institutions participating in this continuation procurement increased by 40%. , The procurement of stents increased by 30%.
At present, the National Medical Insurance Bureau has launched 7 batches of centralized procurement of drugs, 3 batches of centralized procurement of high-value medical consumables, and more than 100 batches of provincial centralized procurement.
In the next step, the National Medical Insurance Administration will work with relevant departments to guide the joint procurement and various regions to complete the implementation of the selection results such as the signing of the procurement agreement, the listing of the selected products, and the prepayment of the medical insurance fund to ensure a smooth connection with the previous procurement cycle.